Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lee Website

Jung-Min Lee, M.D.

Selected Publications

1)  Moon DH, Lee J, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Br. J. Cancer. 109: 1072-8, 2013.
2)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013.
3)  Lee JM, Han JJ, Altwerger G, Kohn EC.
Proteomics and biomarkers in clinical trials for drug development.
J Proteomics. 74: 2632-41, 2011.
4)  O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Front Oncol. 4: 42, 2014.
5)  Lee JM, Ledermann JA, Kohn EC.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Ann. Oncol. 25: 32-40, 2014.
6)  Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
J. Natl. Cancer Inst. 106: dju089, 2014.
7)  Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol. 1: 565-569, 2013.
8)  Kohn EC, Romano S, Lee JM.
Clinical implications of using molecular diagnostics for ovarian cancers.
Ann. Oncol. 24 Suppl 10: x22-26, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 8/4/2014.